Trial begins for the suppression of the urge-to-tic and reduction of tics

March 18, 2022

Neurotherapeutics are pleased to announce the start of the randomised double-blind, placebo-controlled, trial of rhythmic 10Hz median nerve stimulation for the suppression of the urge-to-tic and reduction of tics in individuals with Tourette syndrome and chronic tic disorder.

The study is being led by Professor Stephen Jackson and over the next 10 months 135 participants from the UK will take part in the trial from their homes using a trial device. The individuals will either receive active stimulation or sham stimulation over 20 days. The data will be collate and analysed by a team lead by Dr Barbara Morera at the end of the trial.

Company number: 13198315 

Registered Office:
The Ingenuity Centre
University Of Nottingham Innovation Park
Triumph Road

Tourettes Friendly Organisation
All members of the Neurotherapeutics team have completed training with Tourettes Action educating them about Tourettes Syndrome, thus have been awarded with the Tourettes Friendly Organisation badge recognised by Tourettes Action.

Privacy Notice       Cookies

Neupulse and Neutrack are registered trade marks of Neurotherapeutics Ltd

Website by Clifton Media

Back to Top